News

BMJ3d
Treating rheumatoid arthritis to target: recommendations of an international task force - Annals of the Rheumatic Diseases
Background Aiming at therapeutic targets has reduced the risk of organ failure in many diseases such as diabetes or hypertension. Such targets have not been defined for rheumatoid arthritis (RA).
BMJ6d
Validation of a prediction rule for development of rheumatoid arthritis in patients with early undifferentiated arthritis - Annals of the Rheumatic Diseases
Objective: To validate a model which predicts progression from undifferentiated arthritis (UA) to RA, in a Canadian UA cohort. Methods: The prediction rule, comprising variables which are scored from ...
BMJ6d
Mechanical overloading promotes chondrocyte senescence and osteoarthritis development through downregulating FBXW7 - Annals of the Rheumatic Diseases
Objectives To investigate the role of mechanical stress in cartilage ageing and identify the mechanistic association during osteoarthritis (OA) progression. Methods F-box and WD repeat domain ...
BMJ6d
Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at ...
Objective To compare the relative bioavailability, safety and tolerability of oral methotrexate (MTX) and subcutaneous (SC) MTX administered via an auto-injector (MTXAI) in patients with rheumatoid ...
BMJ6d
How to monitor SLE in routine clinical practice
A century ago syphilis was regarded as the great masquerader. Its modern equivalent is lupus. It may present to a wide range of specialists and its outcome, while much improved, remains uncertain in a ...
BMJ6d
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial - Annals of the Rheumatic ...
Background Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. Methods The GLORIA (Glucocorticoid LOw-dose in ...
BMJ6d
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update - Annals of the Rheumatic Diseases
Objectives To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for the most recent developments in the field. Methods ...
BMJ7d
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update - Annals of the Rheumatic Diseases
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on ...
BMJ7d
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update - Annals of the Rheumatic Diseases
Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-EULAR recommendations for the management of axial spondyloarthritis (axSpA). Methods Following the EULAR ...
BMJ8d
The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease - Annals of the Rheumatic Diseases
IgG4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ. Correlation among clinical, serological, radiological and pathological data is required for diagnosis. This work ...
BMJ8d
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study - Annals of the Rheumatic Diseases
Background Baricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor. Methods In this phase III, double-blind 24-week study, 684 biologic disease-modifying antirheumatic drug (DMARD ...
BMJ8d
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study - Annals of the Rheumatic Diseases
Objectives To compare efficacy and safety of various doses of tofacitinib, an oral Janus kinase inhibitor, with placebo in patients with active ankylosing spondylitis (AS, radiographic axial ...